ZNF883: A Potential Drug Target and Biomarker (G169834)

Target Name: ZNF883

NCBI ID: G169834

ZNF883

Other Name(s): zinc finger protein 883 | Zinc finger protein 883 | ZN883_HUMAN

ZNF883: A Potential Drug Target and Biomarker

ZNF883 is a protein that is expressed in various tissues of the body, including the brain, heart, and gastrointestinal tract. It is a member of the Zinc finger gene family (ZNF), which is known for its role in the regulation of gene expression and cell development. ZNF883 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Potential Drug Target

ZNF883 is a strong candidate for drug targeting due to its unique structure and biology. It has a long N-terminus that is involved in protein-protein interactions and is known to play a role in the regulation of cell adhesion, migration, and invasion. ZNF883 is also known to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed. This suggests that ZNF883 may be a useful target for drugs that are designed to inhibit these processes, such as those used to treat cancer.

In addition to its potential as a drug target, ZNF883 is also a promising biomarker for certain diseases. The ZNF gene family has been implicated in the development of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The expression of ZNF genes has been associated with the development of these diseases, and the dysregulation of ZNF gene expression has been implicated in the pathogenesis of these conditions.

Biomarker Potential

The potential use of ZNF883 as a biomarker for disease has been identified through a variety of experiments. For example, studies have shown that ZNF883 is expressed in various tissues of the brain and that it is involved in the regulation of neuronal communication and synaptic plasticity. This suggests that ZNF883 may be a useful biomarker for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition to its potential as a biomarker, ZNF883 has also been shown to be involved in the regulation of cancer cell growth and survival. Studies have shown that ZNF883 is expressed in various types of cancer, including breast, ovarian, and colorectal cancer. The dysregulation of ZNF883 expression has been implicated in the development and progression of these cancers, and the use of drugs that target ZNF883 may be an effective way to treat these conditions.

Drug Development

The development of drugs that target ZNF883 is an active area of research, and there is significant interest in the use of these drugs for a variety of diseases. One approach to drug development that is being explored is the use of small molecules that can modulate ZNF883 expression and activity. These drugs can be used to treat a variety of conditions, including cancer, neurodegenerative diseases, and autoimmune disorders.

Conclusion

ZNF883 is a protein that has significant potential as a drug target and biomarker for a variety of diseases. Its unique structure and biology, as well as its involvement in the regulation of cell adhesion, migration, and angiogenesis, make it an attractive target for drugs that are designed to inhibit these processes. In addition, the dysregulation of ZNF883 expression has been implicated in the development and progression of a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The use of drugs that target ZNF883 may be an effective way to treat these conditions and improve the quality of life for those affected.

Protein Name: Zinc Finger Protein 883

Functions: May be involved in transcriptional regulation

The "ZNF883 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF883 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets